Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists

European Neuropsychopharmacology

Volumn 25, Issue 9, 2015, Pages 1448-1461

  Furman, Cheryse A ^a   Roof, Rebecca A ^a   Moritz, Amy E ^a   Miller, Brittney N ^a   Doyle, Trevor B ^a   Free, R Benjamin ^a   Banala, Ashwini K ^b   Paul, Noel M ^b   Kumar, Vivek ^b   Sibley, Christopher D ^b   Newman, Amy Hauck ^b   Sibley, David R ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Allosteric; Bitopic; Bivalent; D3 receptor; Dopamine antagonists; Dopamine receptor

Indexed keywords

AMIDE; BETA ARRESTIN; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; RADIOLIGAND; SULPIRIDE; DOPAMINE RECEPTOR BLOCKING AGENT; DRD3 PROTEIN, HUMAN; RETINA S ANTIGEN;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING COMPETITION; BINDING SITE; CELL STIMULATION; COMPETITIVE BINDING ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; LUMINESCENCE; MAXIMUM BINDING CAPACITY; PHARMACOPHORE; PRIORITY JOURNAL; RECEPTOR BINDING; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL LINE; CRICETULUS; GENETICS; HUMAN; METABOLISM; PRECLINICAL STUDY; RADIOASSAY;

ALLOSTERIC REGULATION; ANIMALS; ARRESTINS; BETA-ARRESTINS; BINDING, COMPETITIVE; CHO CELLS; CRICETULUS; DOPAMINE ANTAGONISTS; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR STRUCTURE; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D3;

EID: 84941314827     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.11.013     Document Type: Article

References (39)

1. Banala A.K., Levy B.A., Khatri S.S., Furman C.A., Roof R.A., Mishra Y., Griffin S.A., Sibley D.R., Luedtke R.R., Newman A.H. N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity. J. Med. Chem. 2011, 54:3581-3594.
2. Beaulieu J.M., Gainetdinov R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 2011, 63:182-217.
3. Bergman J., Roof R.A., Furman C.A., Conroy J.L., Mello N.K., Sibley D.R., Skolnick P. Modification of cocaine self-administration by buspirone (buspar(R)): potential involvement of D3 and D4 dopamine receptors. Int. J. Neuropsychopharmacol 2013, 16:445-458.
4. Boeckler F., Gmeiner P. The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects. Pharmacol. Ther. 2006, 112:281-333.
5. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22:3099-3108.
6. Chien E.Y., Liu W., Zhao Q., Katritch V., Han G.W., Hanson M.A., Shi L., Newman A.H., Javitch J.A., Cherezov V., Stevens R.C. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 2010, 330:1091-1095.
7. Christopoulos A., Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 2002, 54:323-374.
8. Chun L.S., Free R.B., Doyle T.B., Huang X.P., Rankin M.L., Sibley D.R. D1-D2 dopamine receptor synergy promotes calcium signaling via multiple mechanisms. Mol. Pharmacol. 2013, 84:190-200.
9. Conn P.J., Christopoulos A., Lindsley C.W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nature reviews. Drug Discovery 2009, 8:41-54.
10. Grundt P., Carlson E.E., Cao J., Bennett C.J., McElveen E., Taylor M., Luedtke R.R., Newman A.H. Novel heterocyclic trans olefin analogues of N-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J. Med. Chem. 2005, 48:839-848.
11. Grundt P., Prevatt K.M., Cao J., Taylor M., Floresca C.Z., Choi J.K., Jenkins B.G., Luedtke R.R., Newman A.H. Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. J. Med. Chem. 2007, 50:4135-4146.
12. Heidbreder C.A., Newman A.H. Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann. N. Y. Acad. Sci. 2010, 1187:4-34.
13. Joyce J.N., Millan M.J. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discovery Today 2005, 10:917-925.
14. Keck T.M., Burzynski C., Shi L., Newman A.H. Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design. Adv. Pharmacol. 2014, 69:267-300.
15. Keov P., Sexton P.M., Christopoulos A. Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology 2011, 60:24-35.
16. Keov P., Valant C., Devine S.M., Lane J.R., Scammells P.J., Sexton P.M., Christopoulos A. Reverse engineering of the selective agonist TBPB unveils both orthosteric and allosteric modes of action at the M(1) muscarinic acetylcholine receptor. Mol. Pharmacol. 2013, 84:425-437.
17. Kumar R., Riddle L., Griffin S.A., Grundt P., Newman A.H., Luedtke R.R. Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology 2009, 56:944-955.
18. Lane J.R., Abdul-Ridha A., Canals M. Regulation of G protein-coupled receptors by allosteric ligands. ACS Chem. Neurosci. 2013, 4:527-534.
19. Lane J.R., Donthamsetti P., Shonberg J., Draper-Joyce C.J., Dentry S., Michino M., Shi L., Scammells P.J., Capuano B., Sexton P.M., Javitch J.A., Christopoulos A. A new mechanism of allostery in a G protein-coupled receptor dimer. Nat Chem Biol. 2014, 10(9):745-752.
20. Lane J.R., Sexton P.M., Christopoulos A. Bridging the gap: bitopic ligands of G-protein-coupled receptors. Trends Pharmacol. Sci. 2013, 34:59-66.
21. Lober S., Hubner H., Tschammer N., Gmeiner P. Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates. Trends Pharmacol. Sci. 2011, 32:148-157.
22. May L.T., Leach K., Sexton P.M., Christopoulos A. Allosteric modulation of G protein-coupled receptors. Ann. Rev. Pharmacol. Toxicol. 2007, 47:1-51.
23. Micheli F., Heidbreder C. Dopamine D3 receptor antagonists: a patent review (2007-2012). Expert Opin. Ther. Patents 2013, 23:363-381.
24. Michino M., Donthamsetti P., Beuming T., Banala A., Duan L., Roux T., Han Y., Trinquet E., Newman A.H., Javitch J.A., Shi L. A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors. Mol. Pharmacol. 2013, 84:854-864.
25. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 1998, 78:189-225.
26. Mugnaini M., Iavarone L., Cavallini P., Griffante C., Oliosi B., Savoia C., Beaver J., Rabiner E.A., Micheli F., Heidbreder C., Andorn A., Merlo Pich E., Bani M. Occupancy of brain dopamine D3 receptors and drug craving: a translational approach. Neuropsychopharmacology 2013, 38:302-312. (official publication of the American College of Neuropsychopharmacology).
27. Newman A.H., Beuming T., Banala A.K., Donthamsetti P., Pongetti K., LaBounty A., Levy B., Cao J., Michino M., Luedtke R.R., Javitch J.A., Shi L. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. J. Med. Chem. 2012, 55:6689-6699.
28. Newman A.H., Blaylock B.L., Nader M.A., Bergman J., Sibley D.R., Skolnick P. Medication discovery for addiction: translating the dopamine D3 receptor hypothesis. Biochem. Pharmacol. 2012, 84:882-890.
29. Newman A.H., Cao J., Bennett C.J., Robarge M.J., Freeman R.A., Luedtke R.R. N-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl)arylcarboxamides as novel dopamine D(3) receptor antagonists. Bioorg. Med. Chem. Lett. 2003, 13:2179-2183.
30. Newman A.H., Grundt P., Cyriac G., Deschamps J.R., Taylor M., Kumar R., Ho D., Luedtke R.R. N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. J. Med.Chem. 2009, 52:2559-2570.
31. Riddle L.R., Kumar R., Griffin S.A., Grundt P., Newman A.H., Luedtke R.R. Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on L-dopa dependent animal involuntary movements in rats. Neuropharmacology 2011, 60:284-294.
32. Ross S., Peselow E. Pharmacotherapy of addictive disorders. Clin. Neuropharmacol. 2009, 32:277-289.
33. Sibley D.R., Monsma F.J. Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 1992, 13:61-69.
34. Silvano E., Millan M.J., Mannoury la Cour C., Han Y., Duan L., Griffin S.A., Luedtke R.R., Aloisi G., Rossi M., Zazzeroni F., Javitch J.A., Maggio R. The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors. Mol. Pharmacol. 2010, 78:925-934.
35. Valant C., Gregory K.J., Hall N.E., Scammells P.J., Lew M.J., Sexton P.M., Christopoulos A. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J. Biol. Chem. 2008, 283:29312-29321.
36. Valant C., May L.T., Aurelio L., Chuo C.H., White P.J., Baltos J.A., Sexton P.M., Scammells P.J., Christopoulos A. Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:4614-4619.
37. Valant C., Robert Lane J., Sexton P.M., Christopoulos A. The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 2012, 52:153-178.
38. Valant C., Sexton P.M., Christopoulos A. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. Mol. Intervent. 2009, 9:125-135.
39. Wootten D., Christopoulos A., Sexton P.M. Emerging paradigms in GPCR allostery: implications for drug discovery. Nature reviews. Drug Discovery 2013, 12:630-644.